MX2021003131A - Antagonista de prostanoide tipo d (dp). - Google Patents

Antagonista de prostanoide tipo d (dp).

Info

Publication number
MX2021003131A
MX2021003131A MX2021003131A MX2021003131A MX2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A MX 2021003131 A MX2021003131 A MX 2021003131A
Authority
MX
Mexico
Prior art keywords
receptor
useful
acceptable salts
nervous system
central nervous
Prior art date
Application number
MX2021003131A
Other languages
English (en)
Inventor
Atsushi Naganawa
Keisuke Hanada
Masaki Asada
Satonori Higuchi
Yasuhiro Takeda
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2021003131A publication Critical patent/MX2021003131A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

La presente invención está dirigida al problema de proporcionar un antagonista del receptor de DP. Los compuestos representados por la fórmula general (I): (en la fórmula, todos los símbolos son como se definen en la descripción) y sus sales farmacológicamente aceptables tienen actividad antagonista del receptor de DP y son altamente seguros y, por lo tanto, son útiles como ingredientes activos de productos farmacéuticos para enfermedades mediadas por el receptor de DP. Además, los compuestos representados por la fórmula general (I) y sus sales farmacológicamente aceptables tienen una excelente capacidad para migrar al sistema nervioso central y, por lo tanto, son útiles como agentes para la prevención y/o tratamiento de enfermedades que involucran a los receptores de DP ubicados en el sistema nervioso central entre las enfermedades mediadas por el receptor de DP, es decir, los trastornos del sueño-vigilia.
MX2021003131A 2018-09-20 2019-09-19 Antagonista de prostanoide tipo d (dp). MX2021003131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018175758 2018-09-20
PCT/JP2019/036725 WO2020059790A1 (ja) 2018-09-20 2019-09-19 Ｄｐアンタゴニスト

Publications (1)

Publication Number Publication Date
MX2021003131A true MX2021003131A (es) 2021-05-14

Family

ID=69888481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003131A MX2021003131A (es) 2018-09-20 2019-09-19 Antagonista de prostanoide tipo d (dp).

Country Status (15)

Country Link
US (2) US11319296B2 (es)
EP (1) EP3854781A4 (es)
JP (2) JP7021709B2 (es)
KR (2) KR20220107330A (es)
CN (1) CN112739680A (es)
AU (1) AU2019341082A1 (es)
BR (1) BR112021005260A2 (es)
CA (1) CA3113210A1 (es)
IL (2) IL310383A (es)
MX (1) MX2021003131A (es)
PH (1) PH12021550549A1 (es)
SG (1) SG11202102566YA (es)
TW (2) TWI822457B (es)
WO (1) WO2020059790A1 (es)
ZA (1) ZA202101887B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005260A2 (pt) 2018-09-20 2021-06-15 Ono Pharmaceutical Co., Ltd. antagonista de dp
WO2021187547A1 (ja) * 2020-03-19 2021-09-23 小野薬品工業株式会社 フェニル酢酸化合物の結晶
JP2024016311A (ja) * 2020-12-24 2024-02-07 小野薬品工業株式会社 Ｅｐ２アンタゴニスト

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63159342A (ja) 1985-04-03 1988-07-02 Yamanouchi Pharmaceut Co Ltd 新規カルボン酸化合物
US4994479A (en) * 1985-04-03 1991-02-19 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives and anti-allergic use thereof
ATE516277T1 (de) * 2002-03-19 2011-07-15 Ono Pharmaceutical Co Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
US20050006047A1 (en) 2003-07-10 2005-01-13 General Electric Company Investment casting method and cores and dies used therein
KR20060080197A (ko) * 2003-09-17 2006-07-07 오노 야꾸힝 고교 가부시키가이샤 카르복실산 화합물 및 이들을 유효 성분으로서 함유하는의약 조성물
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
JP5017103B2 (ja) 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
JP2009022687A (ja) 2007-07-24 2009-02-05 Kojima:Kk テーブル間の補助天板接続構造
TWI410410B (zh) * 2007-08-10 2013-10-01 Ono Pharmaceutical Co Phenylacetic acid compounds
AU2012314508A1 (en) 2011-09-26 2014-02-27 Grunenthal Gmbh Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands
JP2020502189A (ja) 2016-12-20 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インドールアミン２，３−ジオキシゲナーゼのモジュレーター
JP6533249B2 (ja) 2017-04-21 2019-06-19 山佐株式会社 遊技機用基板ケースの取り付け構造及び遊技機
US20210139467A1 (en) 2017-06-28 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
BR112021005260A2 (pt) 2018-09-20 2021-06-15 Ono Pharmaceutical Co., Ltd. antagonista de dp

Also Published As

Publication number Publication date
US20220204468A1 (en) 2022-06-30
KR102425709B1 (ko) 2022-07-28
CA3113210A1 (en) 2020-03-26
KR20220107330A (ko) 2022-08-02
JP2022058610A (ja) 2022-04-12
IL310383A (en) 2024-03-01
EP3854781A4 (en) 2022-02-23
IL281433A (en) 2021-04-29
US11319296B2 (en) 2022-05-03
BR112021005260A2 (pt) 2021-06-15
TW202308986A (zh) 2023-03-01
WO2020059790A1 (ja) 2020-03-26
KR20210065944A (ko) 2021-06-04
CN112739680A (zh) 2021-04-30
JPWO2020059790A1 (ja) 2021-09-02
AU2019341082A1 (en) 2021-04-15
TWI784199B (zh) 2022-11-21
JP7338711B2 (ja) 2023-09-05
TW202023535A (zh) 2020-07-01
PH12021550549A1 (en) 2022-02-14
US20220033371A1 (en) 2022-02-03
EP3854781A1 (en) 2021-07-28
JP7021709B2 (ja) 2022-02-17
ZA202101887B (en) 2022-10-26
TWI822457B (zh) 2023-11-11
SG11202102566YA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
PH12021550549A1 (en) Dp antagonist
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MX2023007192A (es) Inhibidores de prmt5.
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
EA202091256A1 (ru) Новые антагонисты рецептора брадикинина
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
EA036542B9 (ru) Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
ZA202206266B (en) Pd-l1 antagonist compound
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
CY1123185T1 (el) Παραγωγα ινδολιου
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
AU2016407426A1 (en) Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist
MX2021009082A (es) Compuestos quimicos.
BR112015015663A2 (pt) novo derivado de benzoazepina e uso médico do mesmo
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2